AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19684043
Drug: Recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant FSH (200 IU daily injections)
Trial: 11878407
Drug: Ritonavir 400
RxNorm normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 400 mg/saquinavir 400 mg twice daily plus one NRTI
Trial: 11878407
Drug: Indinavir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 800 mg once every 8 hours plus two NRTIs
Trial: 9894650
Drug: Transvenous lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transvenous lead system with additional subcutaneous lead
Trial: 8000154
Drug: Increased trace
RxNorm normalized name: Trace metal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased trace element intake (4.5 mg Cu, 190 micrograms Se, and 40 mg Zn/day)
Trial: 31608373
Drug: Program 4
RxNorm normalized name: Program 410 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Program 4 (community-based HIV care program + nutritional education + food supplement)
Trial: 31608373
Drug: Programs 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programs 3 (community-based HIV care program + food supplement) and 4 (all elements of Programs 1-3)
Trial: 21564071
Drug: Methotrexate 15
RxNorm normalized name: methotrexate 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 15 mg weekly for 8 weeks, then 15 mg weekly for ER, 20 mg weekly for 4 weeks for LR, or 25 mg weekly for LN if not achieving PASI 50.
Trial: 21564071
Drug: Methotrexate 20
RxNorm normalized name: METHOTREXATE 20MG/0.8ML SOLN INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 20 mg weekly for late responders (LR) after initial 15 mg weekly.
Trial: 21564071
Drug: Methotrexate 25
RxNorm normalized name: methotrexate 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 25 mg weekly for late nonresponders (LN) if not achieving PASI 50 at week 12.
Trial: 14514222
Drug: 2.8 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.8 mm neck implants
Trial: 14514222
Drug: Neck implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck implants
Trial: 8403788
Drug: Hormone infusion
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone infusion study (glucagon, adrenaline, noradrenaline, cortisol, growth hormone)
Trial: 8403788
Drug: Hypoglycaemia study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypoglycaemia study (plasma glucose lowered to 2.8 mmol/l)
Trial: 30877742
Drug: M-mZnO (20.90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-mZnO (20.90 m2/g)
Trial: 30877742
Drug: Micronized ZnO
RxNorm normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micronized ZnO groups (S-mZnO, M-mZnO, L-mZnO)
Trial: 26414653
Drug: Etoricoxib (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (90 mg)
Trial: 15352967
Drug: Diclofenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (75 mg)
Trial: 26414653
Drug: Etoricoxib (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (90 mg) and Diclofenac (75 mg)
Trial: 7805083
Drug: Therapy for
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy for DVT based on anatomic extent of thrombus
Trial: 31726034
Drug: Topical prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prednisolone acetate 1% (PA 1%) self-administered daily (tapered schedule, days 0‐28)
Trial: 31726034
Drug: Topical prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prednisolone acetate 1% (PA 1%)
Trial: 22776627
Drug: Helmet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helmet therapy
Trial: 22859320
Drug: Original salbutamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original salbutamol (5 mg, 20 drops in nebulizing solution)
Trial: 22859320
Drug: Similar salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Similar salbutamol (5 mg, 20 drops in nebulizing solution)
Trial: 21211337
Drug: Intratympanic methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic methylprednisolone injection (62.5 mg/ml) infused at a rate of 10 microl/h for 14 days
Trial: 12742294
Drug: Bucindolol (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bucindolol (a beta-blocker)
Trial: 14564594
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of 8 ml of physiological saline after spinal hyperbaric tetracaine
Trial: 14564594
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of 8 ml of physiological saline after spinal isobaric tetracaine
Trial: 14564594
Drug: Spinal hyperbaric
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal hyperbaric tetracaine without epidural injection
Trial: 14564594
Drug: Spinal isobaric
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal isobaric tetracaine without epidural injection
Trial: 27448700
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity atorvastatin (40 mg/day)
Trial: 27448700
Drug: Moderate intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate intensity atorvastatin (20 mg/day)
Trial: 10198862
Drug: Asymmetric corneal
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asymmetric corneal tunnel incisions with an L‐shaped entrance and a concave exit
Trial: 2184874
Drug: Sensory integration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory integration (SI) sessions, about 13 weekly sessions, each of 1 hour duration
Trial: 385456
Drug: Hydrocortisate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisate treatment
Trial: 21917766
Drug: ELND005 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELND005 250 mg
Trial: 19074463
Drug: L-T(4) withdrawal
RxNorm normalized name: (T,G)-A-L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-T(4) withdrawal (37 days); 21 patients received (131)I (2.02+/‐0.22 GBq; 54.6+/‐5.9 mCi)
Trial: 19074463
Drug: rhTSH stimulation;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTSH stimulation; 21 patients received (131)I (1.97+/‐0.18 GBq; 53.2+/‐4.9 mCi) 24 h after rhTSH (0.9 mg)
Trial: 16696817
Drug: Renzapride 2
RxNorm normalized name: Renzapride
DrugBank: Renzapride (DB04917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renzapride 2 mg o.d.
Trial: 20163375
Drug: Renzapride 2
RxNorm normalized name: Renzapride
DrugBank: Renzapride (DB04917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renzapride 2 mg b.d.
Trial: 11737382
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg per day)
Trial: 9764979
Drug: IFN-alpha treatment
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha treatment for 24 weeks
Trial: 30058418
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (VitC) treatment group
Trial: 30058418
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (VitC) non-treatment group
Trial: 9377616
Drug: Voglibose 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose 0.3 mg
Trial: 8385844
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (two doses + booster)
Trial: 8385844
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (booster dose)
Trial: 31228383
Drug: Complex non-drug
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex non-drug programs including exercise therapy, drinking balneotherapy, multivitamins, vibrotherapy, chromotherapy, melody therapy, aromatherapy, aeroionotherapy
Trial: 25420207
Drug: Rasagiline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline (1 or 2 mg/d)
Trial: 21663680
Drug: High calorie
RxNorm normalized name: High calorie formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calorie high protein supplement for forty days in addition to their diet of choice
Trial: 16836625
Drug: Disease management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease management program including screening, patient education, drug therapy with paroxetine, and supportive contacts.
Trial: 16836625
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (control group) where general practitioners were blind to the screening results and treatment was not restricted.
Trial: 15523172
Drug: Heparin group
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin group (20-ml saline-flush followed by 2 ml of 1,000 U/ml heparin-lock)
Trial: 15523172
Drug: Saline group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline group (20-ml saline-flush once a day for each lumen)
Trial: 11199329
Drug: CD14 CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD14 CC genotype
Trial: 11199329
Drug: IL-6-174 CC
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6-174 CC genotype
Trial: 9261525
Drug: Granisetron, dexamethasone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron, dexamethasone, and their combination (exact dosages and duration not specified)
Trial: 8392825
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg granisetron
Trial: 10882331
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg granisetron
Trial: 8392825
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg granisetron
Trial: 3080282
Drug: Misoprostol 100
RxNorm normalized name: MISOPROSTOL 100MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 100 micrograms qid (without antacid)
Trial: 3080282
Drug: Misoprostol 50
RxNorm normalized name: diclofenac-misoprostol 50 mg-200 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 50 micrograms qid (with limited antacid)
Trial: 3080282
Drug: Misoprostol 200
RxNorm normalized name: MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 200 micrograms qid (with limited antacid)
Trial: 25906974
Drug: Personalized dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized dosing strategy
Trial: 25906974
Drug: Standardized dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized dosing strategy
Trial: 17019663
Drug: Early warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early warfarin administration (12 hr after TCC placement) with ticlopidine 250 mg/die
Trial: 17019663
Drug: Warfarin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin administration after the first thrombosis/malfunction episode with ticlopidine 250 mg/die
Trial: 10735893
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy (Hfx RT) with concurrent low-dose daily cisplatin (6 mg/m²)
Trial: 10735893
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation therapy (Hfx RT) alone
Trial: 2412041
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg twice daily for 4 weeks
Trial: 2412041
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg twice daily for 4 weeks
Trial: 26749220
Drug: Huoxue-Tongluo lyophilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 3 g
Trial: 26749220
Drug: Huoxue-Tongluo lyophilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 6 g (multiple-dose, once daily)
Trial: 26749220
Drug: Huoxue-Tongluo lyophilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 9 g
Trial: 26749220
Drug: Huoxue-Tongluo lyophilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 6 g
Trial: 26749220
Drug: Huoxue-Tongluo lyophilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huoxue-Tongluo lyophilized powder for injection (HTLPI)
Trial: 24466245
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) 25 mg/kg
Trial: 24466245
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) 50 mg/kg
Trial: 23143762
Drug: No local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No local therapy (noL)
Trial: 11591234
Drug: MCT meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT meal (15 g fat)
Trial: 11591234
Drug: Linoleate meal
RxNorm normalized name: linoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linoleate meal (50 g fat)
Trial: 7520210
Drug: Chlorthalidone (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (12.5 and 25 mg/day)
Trial: 31948507
Drug: Specific program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific program components used in treatment procedures
Trial: 31021980
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 35 mg orally twice a day for three months, in addition to conventional treatments for angina.
Trial: 31021980
Drug: Conventional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatments for angina only.
Trial: 28499583
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (epirubicin 60 mg/m2 per day plus ifosfamide 3 g/m2 per day, repeated every 21 days)
Trial: 28499583
Drug: Histotype-tailored chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histotype-tailored chemotherapy (various regimens based on histological subtype)
Trial: 28499583
Drug: Histotype-tailored chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histotype-tailored chemotherapy
Trial: 24183196
Drug: Warmed irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed irrigation solution at 32°C ± 2°C (89.6°F ± 3.6°F)
Trial: 24183196
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature irrigation solution (Control)
Trial: 17399635
Drug: Corticosteroids (intermediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (intermediate doses of 50-210 mg dexamethasone equivalent)
Trial: 17399635
Drug: Corticosteroids (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (lower doses up to 8 mg)
Trial: 17399635
Drug: Corticosteroids (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (higher doses 236-2850 mg)
Trial: 2008948
Drug: Midazolam 0.4-5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.4-5.0 mg.kg-1
Trial: 2008948
Drug: Midazolam 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.3 mg.kg-1
Trial: 2008948
Drug: Midazolam 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 1.0 mg.kg-1 or greater
Trial: 2008948
Drug: Midazolam 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 2.0 mg.kg-1 or greater
Trial: 6800869
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (low-dose, 375 mg/day)
Trial: 6800869
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (high-dose, 750 mg/day)
Trial: 6800869
Drug: High-dose chenodeoxycholic
RxNorm normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chenodeoxycholic acid
Trial: 6800869
Drug: High-dose chenodeoxycholic
RxNorm normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chenodeoxycholic acid (women)
Trial: 223950
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid therapy
Trial: 31088090
Drug: Dexmedetomidine (DXM)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DXM) 0.5 mcg/kg with 0.5% ropivacaine 20 mL
Trial: 31088090
Drug: Dexamethasone (DXA)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DXA) 8 mg with 0.5% ropivacaine 20 mL
Trial: 29295513
Drug: 10 µg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg/day vitD3
Trial: 29295513
Drug: 10 µg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg/day 25OH‐D3
Trial: 29295513
Drug: 10 µg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg/day vitD2
Trial: 22658512
Drug: Early salvage
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early salvage hormonal therapy (PSA≤10 ng/mL and absent distant metastases)
Trial: 22658512
Drug: Late salvage
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late salvage hormonal therapy (PSA>10 ng/mL and absent distant metastases)
Trial: 22658512
Drug: Late salvage
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late salvage hormonal therapy (distant metastases)
Trial: 2666080
Drug: Effervescent tablets
RxNorm normalized name: Hydralyte Effervescent Tablets Berry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent tablets A (161 mg daily)
Trial: 2666080
Drug: Effervescent tablets
RxNorm normalized name: Hydralyte Effervescent Tablets Berry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent tablets A* (161 mg daily)
Trial: 2666080
Drug: Proprietary iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary iron preparation B (150 mg daily)
Trial: 909253
Drug: Euthyscope treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euthyscope treatment
Trial: 30097995
Drug: Insulin Degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin Degludec
Trial: 29713962
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine U100
Trial: 18834692
Drug: Treatment seekers
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment seekers
Trial: 14993771
Drug: Nicorandil (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (4 mg iv and 4 mg ic before reperfusion, followed by continuous infusion at 4 mg/h for 24 h)
Trial: 14993771
Drug: Magnesium (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (10 mmol iv before reperfusion, followed by continuous infusion at 0.4 mmol/h for 24 h)
Trial: 11782040
Drug: Refined estimator
RxNorm normalized name: refined almond oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined estimator for the variance of the treatment effect estimator
Trial: 11406840
Drug: Proposed test
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed test for overall treatment effect
Trial: 9293679
Drug: 10% sucralfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sucralfate in sorbolene cream
Trial: 9300326
Drug: SNX‐111 (neuron-specific,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNX‐111 (neuron-specific, N-type, voltage-sensitive calcium channel blocker)
Trial: 2527274
Drug: rHBV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHBV vaccine (2 micrograms)
Trial: 2527274
Drug: rHBV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHBV vaccine (5 micrograms)
Trial: 2527274
Drug: rHBV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHBV vaccine (10 micrograms)